Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 332

1.

[Iatrogenic Cushing syndrome due to the misuse of topical corticosteroids. Pediatric case report].

Edelman S, Buján MM, Cervinia AB.

Arch Argent Pediatr. 2019 Oct 1;117(5):e536-e539. Spanish.

PMID:
31560508
2.

Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.

Edelman SV, Ermakova A, Xiong Y, Sieradzan R, Taylor SD.

J Manag Care Spec Pharm. 2019 Sep 24:1-12. doi: 10.18553/jmcp.2019.19097. [Epub ahead of print]

3.

Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World Study.

Pettus JH, Zhou FL, Shepherd L, Preblick R, Hunt PR, Paranjape S, Miller KM, Edelman SV.

Diabetes Care. 2019 Sep 23. pii: dc190830. doi: 10.2337/dc19-0830. [Epub ahead of print]

PMID:
31548241
4.

Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures.

Pettus JH, Kushner JA, Valentine V, Wood R, Pang C, Paranjape S, Berria R, Deluzio A, Edelman SE.

Diabetes Technol Ther. 2019 Jun;21(6):336-343. doi: 10.1089/dia.2019.0027. Epub 2019 May 16.

5.

Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.

Boeder S, Edelman SV.

Diabetes Obes Metab. 2019 Apr;21 Suppl 2:62-77. doi: 10.1111/dom.13749. Review.

PMID:
31081593
6.

Eliciting allergens and treatment of anaphylaxis: Report of the finnish national anaphylaxis registry.

Edelman SM, Kukkonen AK, Mäkelä MJ.

Allergy. 2019 May 9. doi: 10.1111/all.13858. [Epub ahead of print] No abstract available.

PMID:
31070796
7.

Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.

Pettus J, Gill J, Paranjape S, Stewart J, Malla S, Edelman S, Bergenstal RM, Bode B.

Diabetes Obes Metab. 2019 Aug;21(8):1906-1913. doi: 10.1111/dom.13751. Epub 2019 May 9.

PMID:
30993855
8.

Beyond uncertainty: A broader scope for "incentive hope" mechanisms and its implications.

Linkovski O, Weinbach N, Edelman S, Feldman MW, Lotem A, Kolodny O.

Behav Brain Sci. 2019 Jan;42:e44. doi: 10.1017/S0140525X18002029.

PMID:
30940254
9.

Physician-patient communication at prescription of an additional oral drug for type 2 diabetes and its links to patient outcomes - New findings from the global IntroDia® study.

Edelman S, Belton A, Down S, Alzaid A, Capehorn M, Gamerman V, Nagel F, Lee J, Emmerson J, Polonsky WH.

Diabetes Res Clin Pract. 2019 Mar;149:89-97. doi: 10.1016/j.diabres.2019.01.020. Epub 2019 Jan 24.

PMID:
30685350
10.

A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes.

Davies M, Bain S, Charpentier G, Flacke F, Goyeau H, Woloschak M, Hasslacher C, Vespasiani G, Edelman S.

J Diabetes Sci Technol. 2019 Sep;13(5):881-889. doi: 10.1177/1932296818821706. Epub 2019 Jan 15.

PMID:
30646755
11.

Physician experiences when discussing the need for additional oral medication with type 2 diabetes patients: Insights from the cross-national IntroDia® study.

Down S, Alzaid A, Polonsky WH, Belton A, Edelman S, Gamerman V, Nagel F, Lee J, Emmerson J, Capehorn M.

Diabetes Res Clin Pract. 2019 Feb;148:179-188. doi: 10.1016/j.diabres.2019.01.012. Epub 2019 Jan 11.

PMID:
30641173
12.

Reference Guide for Integrating Continuous Glucose Monitoring Into Clinical Practice.

Kruger DF, Edelman SV, Hinnen DA, Parkin CG.

Diabetes Educ. 2019 Feb;45(1_suppl):3S-20S. doi: 10.1177/0145721718818066. Epub 2018 Dec 13. Review.

PMID:
30541402
13.

Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring.

Edelman SV, Argento NB, Pettus J, Hirsch IB.

Diabetes Care. 2018 Nov;41(11):2265-2274. doi: 10.2337/dc18-1150. Review.

PMID:
30348844
14.
15.

Recommendations for Initiating Use of Afrezza Inhaled Insulin in Individuals with Type 1 Diabetes.

Pettus J, Santos Cavaiola T, Edelman SV.

Diabetes Technol Ther. 2018 Jun;20(6):448-451. doi: 10.1089/dia.2017.0463. Epub 2018 Jun 14. Review.

PMID:
29901406
16.

Significant correlation between peripheral blood CD34+ cell count in children prior to aphaeresis and CD34+ cell yield following aphaeresis: A single-center experience.

Rosenfeld-Keidar H, Eshel R, Pinhasov A, Bitan M, Edelman S, Broitman M, Dvir R, Sadot E, Levin D, Manisterski M, Berger-Achituv S, Elhasid R.

Pediatr Transplant. 2018 May;22(3):e13150. doi: 10.1111/petr.13150. Epub 2018 Mar 2.

PMID:
29498177
17.

A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.

Dolinar R, Lavernia F, Edelman S.

Endocr Pract. 2018 Feb;24(2):195-204. doi: 10.4158/EP161728.RA. Review.

PMID:
29466056
18.

The evolution of the capacity for language: the ecological context and adaptive value of a process of cognitive hijacking.

Kolodny O, Edelman S.

Philos Trans R Soc Lond B Biol Sci. 2018 Apr 5;373(1743). pii: 20170052. doi: 10.1098/rstb.2017.0052. Review.

19.

Component-resolved diagnosis in selecting patients for yellowjacket venom immunotherapy.

Kukkonen AK, Pelkonen AS, Edelman SM, Kauppi PM, Mäkelä MJ.

Ann Allergy Asthma Immunol. 2018 Feb;120(2):184-189. doi: 10.1016/j.anai.2017.11.012.

PMID:
29413342
20.

Response to Comment on Edelman and Polonsky. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care 2017;40:1425-1432.

Edelman SV, Polonsky WH.

Diabetes Care. 2018 Feb;41(2):e18. doi: 10.2337/dci17-0050. No abstract available.

PMID:
29358472
22.

Fundamental computational constraints on the time course of perception and action.

Edelman S, Moyal R.

Prog Brain Res. 2017;236:121-141. doi: 10.1016/bs.pbr.2017.05.006. Epub 2017 Jul 18. Review.

PMID:
29157408
23.

Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence.

Carls GS, Tan R, Zhu JY, Tuttle E, Yee J, Edelman SV, Polonsky WH.

Obes Sci Pract. 2017 Jul 20;3(3):342-351. doi: 10.1002/osp4.116. eCollection 2017 Sep.

24.
25.

Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.

Carls GS, Tuttle E, Tan RD, Huynh J, Yee J, Edelman SV, Polonsky WH.

Diabetes Care. 2017 Nov;40(11):1469-1478. doi: 10.2337/dc16-2725. Epub 2017 Aug 11.

PMID:
28801475
26.

Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control.

Edelman SV, Polonsky WH.

Diabetes Care. 2017 Nov;40(11):1425-1432. doi: 10.2337/dc16-1974. Epub 2017 Aug 11.

PMID:
28801473
27.

Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.

Dhere V, Edelman S, Waller EK, Langston A, Graiser M, Connolly EC, Switchenko JM, Esiashvili N, Khan MK.

Leuk Lymphoma. 2018 Apr;59(4):837-843. doi: 10.1080/10428194.2017.1361027. Epub 2017 Aug 7.

28.

The evolution of cognitive mechanisms in response to cultural innovations.

Lotem A, Halpern JY, Edelman S, Kolodny O.

Proc Natl Acad Sci U S A. 2017 Jul 24. pii: 201620742. doi: 10.1073/pnas.1620742114. [Epub ahead of print]

29.

Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey.

Berard L, Bonnemaire M, Mical M, Edelman S.

Diabetes Obes Metab. 2018 Feb;20(2):301-308. doi: 10.1111/dom.13064. Epub 2017 Sep 12.

30.

Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014.

Carls G, Huynh J, Tuttle E, Yee J, Edelman SV.

Diabetes Ther. 2017 Aug;8(4):863-873. doi: 10.1007/s13300-017-0280-5. Epub 2017 Jun 23.

31.

Where Are We Now? A Clinicians' Guide to the Use of Follow-On Insulin for Patients with Diabetes.

Edelman SV, Hollander PA, Wright EE Jr.

Am J Med. 2017 May;130(5):614. doi: 10.1016/j.amjmed.2017.03.007.

PMID:
28431671
32.

Physician-patient communication at diagnosis of type 2 diabetes and its links to patient outcomes: New results from the global IntroDia® study.

Polonsky WH, Capehorn M, Belton A, Down S, Alzaid A, Gamerman V, Nagel F, Lee J, Edelman S.

Diabetes Res Clin Pract. 2017 May;127:265-274. doi: 10.1016/j.diabres.2017.03.016. Epub 2017 Mar 22.

PMID:
28407552
33.

Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia® ).

Capehorn M, Polonsky WH, Edelman S, Belton A, Down S, Gamerman V, Nagel F, Lee J, Alzaid A.

Diabet Med. 2017 Aug;34(8):1100-1107. doi: 10.1111/dme.13357. Epub 2017 May 21.

PMID:
28370335
34.

Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.

Hirsch JD, Bounthavong M, Arjmand A, Ha DR, Cadiz CL, Zimmerman A, Ourth H, Morreale AP, Edelman SV, Morello CM.

J Manag Care Spec Pharm. 2017 Mar;23(3):318-326. doi: 10.18553/jmcp.2017.23.3.318.

35.

Administration of Biosimilar Insulin Analogs: Role of Devices.

Heinemann L, Fritz I, Khatami H, Edelman SV.

Diabetes Technol Ther. 2017 Feb;19(2):79-84. doi: 10.1089/dia.2016.0263. Review.

PMID:
28118050
36.

Investigating Hypoglycemic Confidence in Type 1 and Type 2 Diabetes.

Polonsky WH, Fisher L, Hessler D, Edelman SV.

Diabetes Technol Ther. 2017 Feb;19(2):131-136. doi: 10.1089/dia.2016.0366. Epub 2016 Dec 20.

PMID:
27997217
37.

Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.

Jacobson TA, Edelman SV, Galipeau N, Shields AL, Mallya UG, Koren A, Davidson MH.

Patient. 2017 Jun;10(3):321-334. doi: 10.1007/s40271-016-0211-y.

38.

Mature Let-7 miRNAs fine tune expression of LIN28B in pluripotent human embryonic stem cells.

Rahkonen N, Stubb A, Malonzo M, Edelman S, Emani MR, Närvä E, Lähdesmäki H, Ruohola-Baker H, Lahesmaa R, Lund R.

Stem Cell Res. 2016 Nov;17(3):498-503. doi: 10.1016/j.scr.2016.09.025. Epub 2016 Sep 24.

39.

Regulation Catches Up to Reality.

Edelman SV.

J Diabetes Sci Technol. 2017 Jan;11(1):160-164. doi: 10.1177/1932296816667749. Epub 2016 Sep 25.

40.

The bottleneck may be the solution, not the problem.

Lotem A, Kolodny O, Halpern JY, Onnis L, Edelman S.

Behav Brain Sci. 2016 Jan;39:e83. doi: 10.1017/S0140525X15000886.

PMID:
27562516
41.

Recommendations for Using Real-Time Continuous Glucose Monitoring (rtCGM) Data for Insulin Adjustments in Type 1 Diabetes.

Pettus J, Edelman SV.

J Diabetes Sci Technol. 2017 Jan;11(1):138-147. doi: 10.1177/1932296816663747. Epub 2016 Aug 20. Review.

42.

System, Subsystem, Hive: Boundary Problems in Computational Theories of Consciousness.

Fekete T, van Leeuwen C, Edelman S.

Front Psychol. 2016 Jul 27;7:1041. doi: 10.3389/fpsyg.2016.01041. eCollection 2016.

43.

Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?

McGill JB, Ahn D, Edelman SV, Kilpatrick CR, Santos Cavaiola T.

Adv Ther. 2016 Aug;33(8):1267-78. doi: 10.1007/s12325-016-0370-1. Epub 2016 Jul 6. Review.

PMID:
27384191
44.

Improvement of Insulin Injection Technique: Examination of Current Issues and Recommendations.

Spollett G, Edelman SV, Mehner P, Walter C, Penfornis A.

Diabetes Educ. 2016 Aug;42(4):379-94. doi: 10.1177/0145721716648017. Epub 2016 May 23. Review.

PMID:
27216036
45.

Between Pleasure and Contentment: Evolutionary Dynamics of Some Possible Parameters of Happiness.

Gao Y, Edelman S.

PLoS One. 2016 May 4;11(5):e0153193. doi: 10.1371/journal.pone.0153193. eCollection 2016.

46.
47.

Unblinded CGM Should Replace Blinded CGM in the Clinical Management of Diabetes.

Ahn D, Pettus J, Edelman S.

J Diabetes Sci Technol. 2016 May 3;10(3):793-8. doi: 10.1177/1932296816632241. Print 2016 May.

48.

Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among Individuals with Type 1 Diabetes Who Use Continuous Glucose Monitoring.

Pettus J, Edelman SV.

Diabetes Technol Ther. 2016 Feb;18 Suppl 2:S234-42. doi: 10.1089/dia.2015.0369.

49.

Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management "Tune Up" Clinic in Complex Patients.

Morello CM, Christopher ML, Ortega L, Khoan J, Rotunno T, Edelman SV, Henry RR, Hirsch JD.

Ann Pharmacother. 2016 Jan;50(1):8-16. doi: 10.1177/1060028015615586. Epub 2015 Nov 5.

PMID:
26546580
50.

The past, present, and future of basal insulins.

Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S.

Diabetes Metab Res Rev. 2016 Sep;32(6):478-96. doi: 10.1002/dmrr.2763. Epub 2015 Nov 25. Review.

PMID:
26509843

Supplemental Content

Loading ...
Support Center